Norepinephrine Bitartrate Injection 16 mg per 250 mL added to 0 — Class II drug recall D-0707-2022
Terminated recall by Athenex Pharma Solutions, LLC, reported 2022-03-30, distributed nationwide. Defective container
| Recall number | D-0707-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Athenex Pharma Solutions, LLC, Clarence, NY, United States |
| Recall initiated | 2022-03-14 |
| Classified | 2022-03-21 |
| Reported by FDA | 2022-03-30 |
| Terminated | 2022-08-04 |
| Distributed | Nationwide (US) |
| Quantity | 5,320 bags |
| Reason classes | packaging |
| NDC | 76154-0476-15 |
| Lot numbers | F2101634, F2101665, F2101666, F2101788, F2101789, F2101811, F2101812, F2101815 |
| Expiration dates | 2022-03-30, 2022-04-02, 2022-04-26, 2022-04-29 |
Product
Norepinephrine Bitartrate Injection 16 mg per 250 mL added to 0.9% Sodium Chloride, 16 mg, 250 mL excel bag, Rx only, Athenex Pharma Solutions, LLC, Clarence, NY, 14031, NDC 76154-476-15
Reason for recall
Defective container
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0707-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.